Viewing Study NCT00742560


Ignite Creation Date: 2025-12-25 @ 2:04 AM
Ignite Modification Date: 2025-12-26 @ 3:39 AM
Study NCT ID: NCT00742560
Status: COMPLETED
Last Update Posted: 2018-01-10
First Post: 2008-08-25
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
Sponsor: AbbVie (prior sponsor, Abbott)
Organization: